3 Australian Undervalued Stocks Trading Up To 41% Below Fair Value

Global trade and growth tensions are putting more scrutiny on where cash actually comes from. That makes Australian stocks with solid cash flow potential, yet priced below estimates of fair value, especially interesting for investors hunting mispriced opportunities. This article highlights three stocks from a cash flow focused value screen that may be overlooked. You will see how their cash generation profiles compare with the prices on offer today.

The three stocks below are only a sample from this cash flow focused idea. The full screen surfaced 44 more companies with similarly compelling cash and valuation stories that are not covered here. If you want to identify and analyze these additional opportunities, head straight to the Undervalued Stocks Based On Cash Flows screener.

Cochlear (ASX:COH)

Cochlear is a global leader in implantable hearing solutions, with its cochlear implant and bone conduction systems, along with replacement processors, accessories and connected care services, forming a single A$2.35b implantable hearing device business that fits neatly with a cash flow focused screen. These high margin products and aftercare services can create recurring revenue as patients upgrade processors and use remote support tools over time. With a market cap of about A$9.34b, Cochlear is a large, established player in hearing health.

Investors watching cash flow focused value ideas may find Cochlear interesting because its Nucleus and Nexa implant systems, Osia platform and connected care tools are all built around long term device use and repeat spend on upgrades and services. The stock screens as trading below an internal fair value estimate based on future cash flows, even as current net margins are under pressure from a recent large one off loss and softer profitability. The key question is whether margin recovery, expanding remote care adoption and a growing installed user base can outweigh those risks and support the cash generation story from here.

Cochlear’s cash rich implant ecosystem may be masking an even bigger story in its cash flow profile. Scan the 2 key rewards and 2 important warning signs to see what the current margins might be quietly signalling for investors.

4DMedical (ASX:4DX)

4DMedical is a medical technology company that develops non invasive four dimensional lung imaging tools such as the XV Scanner, XV LVAS software and CT based CT:VQ. These offerings fit neatly with a screener focused on scalable cash flow potential from software and device licensing. The company currently generates about A$7.06 million in revenue from medical technology research and development of lung function analysis, supported by products that can be licensed and used repeatedly by hospitals and clinics in the United States and Australia. With a market cap of about A$2.16 billion, 4DMedical is a mid sized healthcare stock with a specialist focus on respiratory imaging.

Investors looking at 4DMedical are weighing a cash flow story that is early but interesting. The company’s CT based lung imaging platform and alliances with groups like Philips and Azra AI point to a model built around recurring software and licensing revenue. At the same time, the latest full year result still showed A$7.06 million in sales and a loss of A$204.44 million. A recent capital raise and a reported DCF discount of about 19% create room for a value case. However, past dilution and higher cost funding mean you need to be comfortable with execution risk and slower per share progress. The next chapters in 4DMedical’s adoption and cash generation story are where the real edge for patient investors could sit.

4DMedical’s early revenue and heavy investment spending create a story that many investors may only half understand. To see how the cash burn, partnerships and valuation case fit together, go straight to the analysis report for 4DMedical.

Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals develops radiopharmaceutical imaging agents and therapies that help doctors find and treat cancers, which directly links it to the cash flow focused screener through its commercial Precision Medicine products and late stage Therapeutics pipeline. Most revenue comes from Precision Medicine at about $704.7 million, while Manufacturing Solutions adds roughly $277.1 million, showing that the cash generating imaging portfolio sits alongside a growing manufacturing arm rather than being the only driver. With a market cap of about A$5.6 billion, Telix is a sizeable player in radiopharmaceuticals that some investors may still be getting to know.

Telix Pharmaceuticals may be worth a closer look if you want cash flow potential backed by commercialized products rather than a pipeline-only story. The Illuccix and Gozellix imaging franchise is already producing hundreds of millions in sales. Late stage programs like TLX591 and TLX250 introduce the possibility of additional cash flows, subject to how clinical and regulatory outcomes unfold. At the same time, higher R&D spend, debt that is not comfortably covered by operating cash flow and an SEC subpoena around disclosures keep the overall risk profile elevated. The market reaction following setbacks in 2025 means this is a stock that a DCF model values above the current price, while sentiment remains cautious and may not fully reflect all aspects of the business.

Telix Pharmaceuticals looks like its cash generation from Precision Medicine could be only half the story. To see how the late stage pipeline, valuation gap and regulatory risks really connect, review the 3 key rewards and 2 important warning signs (1 is major!)

Seeking Fresh Alternatives Before Others Catch On

Markets move fast and the strongest ideas often break out quietly. Before momentum starts flying and entry points get caught by the crowd, scan these fresh stock lists and consider your options carefully.

• Target companies with reliable cash generation by reviewing a curated list of solid balance sheet and fundamentals (21 results) while prices and fundamentals still appear aligned for patient investors.
• Explore potential structural growth in computing demand and power needs with a focused set of 39 power grid technology and infrastructure stocks that may be relevant as infrastructure spending changes over time.
• Evaluate opportunities related to the rise of automation by checking a hand picked group of 36 robotics and automation stocks before their stories move from under the radar to wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com